{"Clinical Trial ID": "NCT02364388", "Intervention": ["INTERVENTION 1:", "- Maestro.", "Reference"], "Eligibility": ["\u2022 Inclusion criteria", "Women", "- 18 years or older", "To have an undiagnosed suspicious discovery that may include more than one solid or complex cystic suspect mass, classified by the CDU as BI-RADS 4a or 4b within 3 weeks of initial detection by Imagio", "- Exclusion criteria:", "Have a condition or obstacle that could interfere with the intended field of vision (within a probe or 4 cm of the mass), (i.e. breast implants in the previous 12 months, or tattoos)", "\u2014 Pregnant or lactating", "The patient received chemotherapy for any type of cancer within 90 days of the date of CDU screening"], "Results": ["Performance measures:", "OA/US specification (Downgrade (%) for BI-RADS 4A and 4B) of benign masses", "The result is the percentage of benign masses properly degraded by ultrasonography (OA/US) from a suspected anomaly (4A or 4B) to be benign or probably benign (BI-RADS 2 or 3). BI-RADS is the mammary imaging and data system established by the American College of Radiology. BI-RADS scores vary from 0 to 6, with an increase in the score indicating an increase in the probability of malignancy. BI-RADS score of 4 or more indicates the need for biopsy. Specificity is reported with a confidence interval of 96% using a normal approximation.", "Timeline: CDU images and decision to biopsy during screening. OA/US imaging must be done within 10 days of screening. Biopsy must be done within 30 days of screening.", "Results 1:", "Title of arm/group: MAESTRO", "Description of the arm/group: Basic data", "Total number of participants analysed: 143", "Total number of units analysed", "Type of units Analysis: Average masses (96% Confidence interval)Unity of measurement: percentage of masses: 41.1 (33.1 to 49.6)"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/217 (0.00 per cent)"]}